research

iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript

Seeking Alpha

2 min read

0 likes

⚡ Quantum Brief

iBio’s CEO Martin Brenner unveiled progress on its Myostatin x Activin A bispecific antibody program, positioning it as a next-gen therapy for heart failure-linked pulmonary hypertension during a March 2026 earnings call. The company emphasized dual-target inhibition of Myostatin and Activin A, pathways implicated in cardiac fibrosis and vascular remodeling, aiming to improve outcomes where current treatments fall short. Analysts from firms like Leerink Partners and Oppenheimer probed the program’s differentiation, clinical timeline, and competitive edge, signaling strong investor interest in its novel mechanism. Brenner highlighted preclinical data suggesting the antibody may reverse pulmonary vascular resistance, a key driver of heart failure progression, though human trials remain pending. iBio cautioned that forward-looking statements carry risks, with SEC filings detailing uncertainties around development timelines, regulatory hurdles, and market adoption.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

SA Transcripts159.01K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure March 17, 2026 4:00 PM EDT Company Participants Martin Brenner - CEO, Chief Scientific Officer & DirectorCory Schwartz Conference Call Participants Byunghyun Ahn - Leerink Partners LLC, Research DivisionJay Olson - Oppenheimer & Co. Inc., Research DivisionPatrick Dolezal - LifeSci Capital, LLC, Research DivisionKaey Nakae - Chardan Capital Markets, LLC, Research DivisionCatherine Novack - JonesTrading Institutional Services, LLC, Research DivisionBenjamin Burnett - Wells Fargo Securities, LLC, Research DivisionMayank Mamtani - B. Riley Securities, Inc., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the iBio conference call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Martin Brenner. Please go ahead, sir. Martin BrennerCEO, Chief Scientific Officer & Director Good morning, and thank you for joining us today. Before we begin, I would like to remind you that during this call the company will be making forward-looking statements regarding our current expectations and projections about future events that are subject to risks and uncertainties. References to these risks and uncertainties are disclosed in detail in the company's periodic and current filings with the U.S. Securities and Exchange Commission. No forward-looking statements can be guaranteed and actual results may differ materially from those discussed today. Information on this conference call is provided only as of today, and we undertake no obligation to update these statements, except as required by law. Joining me on the call today is Cory Schwartz, Director and Head of Research and Early Development at iBio. Recently, we have been receiving a great deal of questions about our Myostatin x Activin A Bispecific antibody program as a potential next-generation therapy in heart

Read Original

Source Information

Source: Seeking Alpha

Website: https://seekingalpha.com/feed.xml

Discussion

0 professional contributions

Be the first to add a constructive contribution.